Details for Patent: 6,369,059
✉ Email this page to a colleague
Title: | Tetracyclic derivatives, process of preparation and use |
Abstract: | A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders. |
Inventor(s): | Daugan; Alain Claude-Marie (Les Ulis, FR) |
Assignee: | ICOS Corporation (Bothell, WA) |
Filing Date: | Aug 07, 2000 |
Application Number: | 09/633,431 |
Claims: | 1. A method of treating conditions where inhibition of cGMP-specific PDE is of therapeutic benefit, in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula ##STR20## or salts or solvates thereof, in which: R.sup.0 represents hydrogen, halogen, or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC.sub.1-3 alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, and mixtures thereof; R.sup.2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring; ##STR21## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may he saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-6 alkyl, or R.sup.1 or R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring. 2. The method of claim 1 wherein cGMP levels in a human or nonhuman animal body are elevated. 3. The method of claim 2 wherein the elevated cGMP level provides an antiplatelet, an antineurophil, an antivasospastic, a vasodilatory, a natriuretic, or a diuretic activity. |